Company intelligence / Profile preview

Blue Horizon International

New York, New York, United Statesbluehorizoninternational.com ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

BHI has safely performed more than 4,000 stem cell therapies. Their research shows their cellular products are safe and effective in improving symptoms related to chronic inflammation, spinal cord injury, stroke, and musculoskeletal disorders. The FDA has approved their IND application for a clinical study of cell therapy for acute ischemic stroke.

Therapeutic areas: CardiovascularRheumatologyImmunologyNeurology
Modalities: Stem cell therapiesRegenerative medicineImmunocancer therapy
Industry: Biotech

Drug pipeline

2 assets

mesenchymal stem cells (Wharton’s jelly-derived)

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Wuhan University Department of Medicine and their Biochemistry Institute

Beyond the preview

Go deeper on Blue Horizon International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blue Horizon International.

Explore the full profile